Polaryx Therapeutics (PLYX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Jul, 2026Executive summary
Annual meeting scheduled for September 10, 2026, at 9:00 a.m. Eastern Time, to be held virtually.
Shareholders are encouraged to review proxy materials online and may request paper or email copies at no charge.
Voting matters and shareholder proposals
Election of Class I Directors with nominees Alex Yang, J.D., LL.M, and Mitchel Berger, M.D.
Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Board recommends voting "FOR ALL NOMINEES" and "FOR" the auditor ratification proposal.
Board of directors and corporate governance
Board is presenting two nominees for election as Class I Directors.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Polaryx Therapeutics
- PLX-200 targets multiple rare pediatric LSDs with strong preclinical data and a flexible Phase 2 trial.PLYX
Company presentation28 Jul 2026 - Shareholders will vote on director elections and auditor ratification, with strong governance and oversight.PLYX
Proxy filing28 Jul 2026 - PLX-200 targets multiple rare pediatric LSDs with strong preclinical data and flexible clinical strategy.PLYX
Corporate presentation15 May 2026 - Q1 2026 net loss fell to $2.5M; cash runway extends through Q3 2026, further funding required.PLYX
Q1 202615 May 2026 - Net loss improved to $9.0M in 2025, but cash only funds operations through Q3 2026.PLYX
Q4 202524 Mar 2026 - PLX-200 advances in a flexible Phase 2 trial for rare pediatric LSDs, targeting broad market impact.PLYX
Corporate presentation16 Mar 2026 - Pre-revenue biotech with a lead LSD therapy pursues Nasdaq direct listing, faces funding needs.PLYX
Registration Filing3 Feb 2026 - Direct listing on Nasdaq for a rare disease biotech with no revenue and high clinical risk.PLYX
Registration Filing3 Feb 2026 - Direct listing of 47.3M shares for rare disease biotech with no proceeds, high risk, and key trial ahead.PLYX
Registration Filing3 Feb 2026